Babraham scientists highlighted for contribution to UK economy


Scientists and managers at the Babraham Institute have been highlighted as being among the leading bioscience groups contributing to the UK’s economic and social wellbeing.

Babraham Bioscience Technologies Ltd, the wholly owned subsidiary and trading arm of the Babraham Institute was highlighted at a recent event at HM Treasury, run by the Biotechnology and Biological Sciences Research Council (BBSRC). They were highlighted for their work delivering a high impact knowledge transfer remit through the development of a bioincubator on the Babraham Institute campus to stimulate commercialisation and knowledge transfer. Over 30 biotech companies that develop technology platforms, products and services occupy the site and employ over 300 staff


The event, ‘Bioscience:Biomillions’, illustrated how the UK’s excellent bioscience research base, principally funded by BBSRC with over £400M of public money each year, is delivering substantial economic and social impact. Other high impact bioscience research on show included work to understand and defeat hospital superbugs, research to understand ageing and to develop ways to encourage healthier ageing, and research to help farmers increase crop yields and to cope with a changing climate.


Participants in the event included representatives from the Babraham Institute and Babraham Bioscience Technologies, other bioscientists being highlighted for their contributions, dignitaries including Ian Pearson MP, the Minister of State for Science and Innovation, industry leaders, policy makers and leading academics.


Mr Pearson said: “Bioscience researchers in the UK have not only pursued excellent, world-class research, but they have also been active in ensuring that we all benefit from their efforts.


“In order to remain globally competitive and meet the future challenges of living within our environmental and population limits, it is vital that bioscience researchers continue to maximise the positive economic and social impacts of their research and activities.”


Steve Visscher, BBSRC Interim Chief Executive, said: “The UK’s world class bioscience research base underpins major economic and social sectors such as agriculture, pharmaceuticals, food, healthcare and the environment. Our researchers are amongst the best in the world in terms of the quality of their science but they are also making huge contributions to quality of life for people through economic and social impact.”


The event also highlighted the success of BBSRC initiatives such as the Biotechnology Young Entrepreneurs Scheme in developing the innovators of the future, and the Business Plan Competition in facilitating the birth of new companies.




BBSRC Media Office

Matt Goode, Tel: 01793 413299, email:

Nancy Mendoza, Tel: 01793 413355, email:


Babraham Bioscience Technologies Ltd.

Dr David J Hardman, Chief Executive Officer         Tel: +44 (0)1223 496205
Babraham Bioscience Technologies Ltd               Fax: +44 (0)1223 496020



Dr Claire Cockcroft,

Deputy, Corporate Affairs                                    Tel: +44 (0)1223 496260
Babraham Institute                                             Fax: +44 (0)1223 496002



Nicola Kinsey,

Commercial Liaison Manager                              Tel: +44 (0)1223 496334

Babraham Bioscience Technologies Ltd               Fax: +44 (0)1223 496020





BBSRC recently presented ‘Bioscience:Biomillions’ at HM Treasury to give scientists, policymaker and industry leaders the chance to meet and celebrate the quality of UK bioscience and its contribution to our economy and society. Nearly 50 top academic researchers were highlighted for their research and social and economic impact.


Full details of ‘Bioscience:Biomillions’, including a complete list of all the bioscientists highlighted for their economic and social impact is available at:


More information about BBSRC knowledge transfer and economic and social impact activities is available at:



The Biotechnology and Biological Sciences Research Council is the UK funding agency for research in the life sciences. Sponsored by Government, BBSRC annually invests around £420M in a wide range of research that makes a significant contribution to the quality of life for UK citizens and supports a number of important industrial stakeholders including the agriculture, food, chemical, healthcare and pharmaceutical sectors.


About Babraham Bioscience Technologies Ltd


Babraham Bioscience Technologies Ltd is the wholly-owned subsidiary and trading arm of the Babraham Institute. Coalescing scientific, technological and commercial excellence, BBT delivers the Knowledge Transfer remit of the Institute through the wider landscape of the Babraham Research Campus, catalysing opportunities for enterprise across the academic and commercial divide. BBT brings together all the elements to support innovation and enable the successful exploitation of research in the biomedical sector based on technologies emanating from the Babraham Institute and bioventures relocating to the Babraham Research Campus.


The Babraham Research Campus is the UK’s leading knowledge-driven Biomedical Park where world-class research, business know-how and entrepreneurial excellence come together to stimulate effective knowledge transfer and bridge the academic and commercial divide. The campus provides a unique and highly successful environment that actively fosters innovation and plays a pivotal role for biomedical start-up companies in the Cambridge region and with delivering innovation at the frontiers of biomedical research. BBT has taken a prominent role regionally, initiating and leading partnerships to promote knowledge and skills flow and has established a reputation for successfully translating innovative science into viable business opportunities through partnerships for wealth creation. This is stimulating inward investment to the campus and contributing to regional development. Building on the success of the incubator model, BBT established a new venture, Aitua Ltd, formerly 'Babraham BioConcepts Ltd'. Aitua works closely with innovators to create and nurture emerging companies from world-class science and technology deriving mainly from the Babraham Institute or locating to the Babraham Research Campus. It will provide seed and early round funding, inject specific expertise and provide access to facilities to companies. BBT’s activities support wider investment in the life sciences to generate and sustain growth of the region’s healthcare economy. Website:


The Babraham Institute is an independent charitable organisation, sponsored by the Biotechnology and Biological Sciences Research Council, carrying out world-leading innovative research and advanced training with relevance to the biomedical, biotechnological, pharmaceutical and healthcare research and user communities. The Institute’s research focuses on the mechanisms of cell signalling and gene regulation, which underlie normal cellular processes and functions, and on how their failure or abnormality may lead to disease. As such, Institute scientists are striving to find cures for conditions where there is currently no treatment or where the existing treatment is not fully effective or causes serious side effects. The latest technologies are being used to study the basis of conditions such as neurodegenerative disorders, foetal abnormality, cancer and diseases of the immune and cardiovascular systems. The commercialisation of the Institute’s research is managed by its trading subsidiary, Babraham Bioscience Technologies Ltd. The Babraham Research Campus is located six miles south-east of Cambridge.  Website:

To read more information, click here.

The Institute is an independent charitable life sciences research institute, strategically funded by the Biotechnology and Biological Sciences Research Council.

Babraham Institute